396 related articles for article (PubMed ID: 26428453)
1. Development of vaccines for Plasmodium vivax malaria.
Mueller I; Shakri AR; Chitnis CE
Vaccine; 2015 Dec; 33(52):7489-95. PubMed ID: 26428453
[TBL] [Abstract][Full Text] [Related]
2. The march toward malaria vaccines.
Hoffman SL; Vekemans J; Richie TL; Duffy PE
Vaccine; 2015 Nov; 33 Suppl 4(Suppl 4):D13-23. PubMed ID: 26324116
[TBL] [Abstract][Full Text] [Related]
3. Potential role of vaccines in elimination of Plasmodium vivax.
White M; Chitnis CE
Parasitol Int; 2022 Oct; 90():102592. PubMed ID: 35489701
[TBL] [Abstract][Full Text] [Related]
4. Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses.
White M; Amino R; Mueller I
Trends Parasitol; 2017 Apr; 33(4):260-263. PubMed ID: 28077251
[TBL] [Abstract][Full Text] [Related]
5. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.
de Jong RM; Tebeje SK; Meerstein-Kessel L; Tadesse FG; Jore MM; Stone W; Bousema T
Immunol Rev; 2020 Jan; 293(1):190-215. PubMed ID: 31840844
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium vivax malaria vaccines: why are we where we are?
Reyes-Sandoval A; Bachmann MF
Hum Vaccin Immunother; 2013 Dec; 9(12):2558-65. PubMed ID: 23978931
[TBL] [Abstract][Full Text] [Related]
7. Plasmodium vivax vaccine research - we've only just begun.
Tham WH; Beeson JG; Rayner JC
Int J Parasitol; 2017 Feb; 47(2-3):111-118. PubMed ID: 27899329
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
[TBL] [Abstract][Full Text] [Related]
9. Investment in malaria research has led to strong pipeline of malaria vaccines, report suggests.
Constable L
Expert Rev Vaccines; 2011 Aug; 10(8):1116. PubMed ID: 21961197
[No Abstract] [Full Text] [Related]
10. Vaccines against Plasmodium vivax: a research challenge.
Patarroyo MA; Calderón D; Moreno-Pérez DA
Expert Rev Vaccines; 2012 Oct; 11(10):1249-60. PubMed ID: 23176656
[TBL] [Abstract][Full Text] [Related]
11. Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation.
Tachibana M; Takashima E; Morita M; Sattabongkot J; Ishino T; Culleton R; Torii M; Tsuboi T
Parasitol Int; 2022 Apr; 87():102525. PubMed ID: 34896614
[TBL] [Abstract][Full Text] [Related]
12. Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development.
Asali S; Raz A; Turki H; Mafakher L; Razmjou E; Solaymani-Mohammadi S
Infect Genet Evol; 2021 Apr; 89():104710. PubMed ID: 33421653
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium vivax - How hidden reservoirs hinder global malaria elimination.
Angrisano F; Robinson LJ
Parasitol Int; 2022 Apr; 87():102526. PubMed ID: 34896312
[TBL] [Abstract][Full Text] [Related]
14. Control and elimination of Plasmodium vivax.
Shanks GD
Adv Parasitol; 2012; 80():301-41. PubMed ID: 23199491
[TBL] [Abstract][Full Text] [Related]
15. Overview: immunology of malaria and progress in malaria vaccine development.
Tharavanij S
Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
[No Abstract] [Full Text] [Related]
16. An update on the search for a Plasmodium vivax vaccine.
Herrera S; Corradin G; Arévalo-Herrera M
Trends Parasitol; 2007 Mar; 23(3):122-8. PubMed ID: 17258937
[TBL] [Abstract][Full Text] [Related]
17. Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination.
Martin TCS; Vinetz JM
Malar J; 2018 Feb; 17(1):89. PubMed ID: 29466991
[TBL] [Abstract][Full Text] [Related]
18. The Biology of
Adams JH; Mueller I
Cold Spring Harb Perspect Med; 2017 Sep; 7(9):. PubMed ID: 28490540
[No Abstract] [Full Text] [Related]
19. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium vivax pre-erythrocytic vaccines.
Reyes-Sandoval A
Parasitol Int; 2021 Oct; 84():102411. PubMed ID: 34166786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
